Ruxolitinib for Therapy of Graft-versus-Host Disease.

Thomas NeumannLaila SchneidewindMartin WeigelAndrzej PlisRem VaizianChristian A SchmidtWilliam Krüger

Published in: BioMed research international (2019)

Ruxolitinib was effective for therapy of acute and chronic GvHD in higher lines in patients without severe diarrhea. Ruxolitinib could replace successfully CNI and high-dose steroids. Further investigations are necessary to define the position of ruxolitinib in GvHD-therapy.

Keyphrases

high dose
end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
liver failure
low dose
allogeneic hematopoietic stem cell transplantation
acute myeloid leukemia
hepatitis b virus
respiratory failure
cell therapy
irritable bowel syndrome